Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Biotechnology
$2.17
-6.28%
Mkt Cap $303.68M
Analyst Ratings
No recent rating data.
Price Target (5 analysts)
$6.50
Range $5.00 – $8.00
Implied Upside
+200.2%
Consensus $6.50 vs current $2.17
NASDAQ·Healthcare·Biotechnology
$2.17
-6.28%
Mkt Cap $303.68M
No recent rating data.
Price Target (5 analysts)
$6.50
Range $5.00 – $8.00
+200.2%
Consensus $6.50 vs current $2.17